Stallergenes Greer

NIH Trial Shows Home-Based Peanut Butter Therapy Successfully Treats High-Threshold Peanut Allergies

3 months ago

• A groundbreaking NIH-sponsored trial demonstrated 100% success rate in helping children with high-threshold peanut allergies tolerate up to three tablespoons of peanut butter through gradual exposure therapy. • The 18-month treatment protocol, using store-bought peanut butter with home-measured doses, offers a safe and accessible option for approximately 800,000 U.S. children with high-threshold peanut allergies. • The study showed 68.4% of treated participants achieved sustained unresponsiveness to peanuts, compared to only 8.6% natural tolerance development in the avoidance group.

Palforzia Receives European Commission Approval for Peanut Allergy Treatment in Toddlers

4 months ago

• The European Commission has approved Palforzia for treating peanut allergies in toddlers aged 1-3, expanding its availability in Europe. • This approval follows the FDA's decision in July 2024, making Palforzia the only oral immunotherapy approved for this age group in both regions. • Palforzia aims to desensitize patients by gradually increasing tolerance to peanuts, reducing the risk of severe allergic reactions from accidental exposure. • The approval is based on the Phase 3 POSEIDON study, which demonstrated Palforzia's efficacy and safety in young children with peanut allergies.

Palforzia Receives Positive CHMP Opinion for Peanut Allergy Treatment in Toddlers

6 months ago

• The European Medicines Agency's CHMP has recommended Palforzia for treating peanut allergies in toddlers aged 1-3, marking a potential expansion of its use. • Palforzia, developed by Stallergenes Greer, aims to desensitize individuals to peanut allergens through controlled oral immunotherapy. • The recommendation is based on the Phase 3 POSEIDON trial, which demonstrated efficacy and a favorable safety profile in young children. • If approved by the European Commission, Palforzia would be the first EMA-approved oral immunotherapy for peanut allergies in this age group.

Nestlé Divests Palforzia to Stallergenes Greer, Exits Peanut Allergy Treatment Market

2 years ago

• Nestlé Health Science has sold its peanut allergy treatment Palforzia to Stallergenes Greer, just three years after acquiring Aimmune Therapeutics for $2.6 billion. • Despite being the first FDA-approved therapy for peanut allergy in children aged 4-17, Palforzia's market performance remained modest due to complex administration requirements and clinical monitoring challenges. • The acquisition positions Stallergenes Greer as the first company to offer both respiratory and food allergy treatments, while Nestlé retains future milestone payments and royalty rights.